




NEURAL REGENERATION

神经再生

KWOK-FAI SO, XIAO-MING XU

Elyssa Siegel



SCIENCE PRESS

NEURAL REGENERATION

Edited by

KWOK-FAI SO

XIAO-MING XU



Science Press
Beijing



ELSEVIER

AMSTERDAM • BOSTON • HEIDELBERG • LONDON
NEW YORK • OXFORD • PARIS • SAN DIEGO
SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO

Academic Press is an imprint of Elsevier



Academic Press is an imprint of Elsevier
32 Jamestown Road, London NW1 7BY, UK
525 B Street, Suite 1800, San Diego, CA 92101-4495, USA
225 Wyman Street, Waltham, MA 02451, USA
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK

Copyright © 2015 Science Press.

ISBN: 978-7-03-044098-3

Published by Science Press & Elsevier Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the Publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

ISBN: 978-0-12-801732-6

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library

Library of Congress Cataloging-in-Publication Data

A catalog record for this book is available from the Library of Congress

For information on all Academic Press publications
visit our website at <http://store.elsevier.com/>

Typeset by TNQ Books and Journals
www.tnq.co.in

Printed and bound in the United States of America



Working together
to grow libraries in
developing countries

www.elsevier.com • www.bookaid.org

List of Contributors

- Larry I. Benowitz** Laboratories for Neuroscience Research in Neurosurgery and F.M. Kirby Neurobiology Center, Children's Hospital Boston, Boston, MA, USA; Departments of Surgery and Ophthalmology and Program in Neuroscience, Harvard Medical School, Boston, MA, USA
- John L. Bixby** The Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Miami, FL, USA; Center for Computational Sciences, University of Miami Miller School of Medicine, Miami, FL, USA; Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL, USA; Department of Molecular & Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL, USA
- Todd J. Brown** Research and Development Service, Richard L. Roudebush VA Medical Center, Indianapolis, IN, USA; Department of Anatomy & Cell Biology, Indiana University School of Medicine, Indianapolis, IN, USA
- Qi Lin Cao** The Vivian L Smith Department of Neurosurgery, University of Texas Health Science Center at Houston, Houston, TX, USA; Center for Stem Cell and Regenerative Medicine, The Brown Foundation Institution of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA
- Dong Feng Chen** Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA; VA Boston Healthcare System, Boston, MA, USA
- Justin Chew** Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA
- Kin-Sang Cho** Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA
- Samuel David** Centre for Research in Neuroscience, The Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
- Lingxiao Deng** Spinal Cord and Brain Injury Research Group, Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Neurological Surgery and Goodman and Campbell Brain and Spine, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, USA
- Fei Ding** Jiangsu Key Laboratory, Nantong University, Nantong, Jiangsu, P.R. China
- Sarah A. Dunlop** Experimental and Regenerative Neurosciences, School of Animal Biology, University of Western Australia, Crawley, Australia
- Keith N. Fargo** Research and Development Service, Edward Hines, Jr. Department of Veterans Affairs Hospital, Hines, IL, USA; Department of Molecular Pharmacology and Therapeutics, Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA; Alzheimer's Association, National Office, Chicago, IL
- Toby A. Ferguson** Shriners Hospitals Pediatric Research Center, Temple University School of Medicine, Philadelphia, PA, USA
- Eileen M. Foecking** Department of Otolaryngology-Head and Neck Surgery, Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA; Research and Development Service, Edward Hines, Jr. Department of Veterans Affairs Hospital, Hines, IL, USA
- Qing-Ling Fu** Otorhinolaryngology Hospital, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
- Mary Pauline Galea** Department of Medicine, The University of Melbourne, VIC, Australia
- Cédric C. Geoffroy** Department of Neurosciences, University of California San Diego, La Jolla, California, USA
- Shu-chao Ge** National Laboratory for Physical Sciences at the Microscale, University of Science and Technology of China, China
- Chenying Guo** Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA
- Jiasong Guo** Department of Histology and Embryology, Southern Medical University, Guangzhou, China; Key Laboratory of Tissue Construction and Detection of Guangdong Province, Guangzhou, China; Institute of Bone Biology, Academy of Orthopedics, Guangdong Province, Guangzhou, China
- Xiaosong Gu** Jiangsu Key Laboratory, Nantong University, Nantong, Jiangsu, P.R. China
- Theo Hagg** Department of Biomedical Sciences, East Tennessee State University, Johnson City, TN, USA
- Cheng He** Institute of Neuroscience and Key Laboratory of Molecular Neurobiology of Ministry of Education, Neuroscience Research Center of Changzheng Hospital, Second Military Medical University, Shanghai, China
- Zhigang He** F.M. Kirby Neurobiology Center, Children's Hospital; Department of Neurology, Harvard Medical School, Boston, MA, USA
- John D. Houle** Department of Neurobiology and Anatomy and Drexel Spinal Cord Research Center, Drexel University College of Medicine, Philadelphia, PA, USA

- Yu-bin Huang** National Laboratory for Physical Sciences at the Microscale, University of Science and Technology of China, China
- Bing Hu** National Laboratory for Physical Sciences at the Microscale, University of Science and Technology of China, China
- Lyn B. Jakeman** Department of Physiology and Cell Biology, Center for Brain and Spinal Cord Repair, The Ohio State University College of Medicine, Columbus, OH, USA
- Kathryn J. Jones** Research and Development Service, Richard L. Roudebush VA Medical Center, Indianapolis, IN, USA; Department of Anatomy & Cell Biology, Indiana University School of Medicine, Indianapolis, IN, USA
- Yoshiki Koriyama** Graduate School and Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Japan; Laboratories for Neuroscience Research in Neurosurgery and F.M. Kirby Neurobiology Center, Children's Hospital Boston, Boston, MA, USA; Departments of Surgery and Ophthalmology and Program in Neuroscience, Harvard Medical School, Boston, MA, USA
- Antje Kroner** Centre for Research in Neuroscience, The Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
- Daniel H.S. Lee** Department of Anatomy, Faculty of Medicine, University of Hong Kong, Hong Kong, China
- Vance P. Lemmon** The Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Miami, FL, USA; Center for Computational Sciences, University of Miami Miller School of Medicine, Miami, FL, USA; Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL, USA
- Shuxin Li** Shriners Hospitals Pediatric Research Center, Temple University School of Medicine, Philadelphia, PA, USA
- Jie Liu** Jiangsu Key Laboratory, Nantong University, Nantong, Jiangsu, P.R. China
- Ahmed Moghieb** Center for Neuroproteomics & Biomarkers Research, Department of Psychiatry, University of Florida, Gainesville, FL, USA; Department of Chemistry, University of Florida, Gainesville, FL, USA
- Paul J. Reier** Department of Neuroscience, University of Florida College of Medicine, Gainesville, FL, USA
- Jennifer Rodger** Experimental and Regenerative Neurosciences, School of Animal Biology, University of Western Australia, Crawley, Australia
- Michael E. Selzer** Shriners Hospitals Pediatric Research Center, Temple University School of Medicine, Philadelphia, PA, USA; Department of Neurology, Temple University School of Medicine, Philadelphia, PA, USA
- Dale R. Sengelaub** Department of Psychological and Brain Sciences and Program in Neuroscience, Indiana University, Bloomington, IN, USA
- Kartavya Sharma** Department of Neurology, UT Southwestern Medical Center, Dallas, TX, USA
- Michael I. Shifman** Shriners Hospitals Pediatric Research Center, Temple University School of Medicine, Philadelphia, PA, USA
- George M. Smith** Shriners Hospitals Pediatric Research Center, Temple University School of Medicine, Philadelphia, PA, USA
- Kwok-Fai So** GHM Institute of CNS Regeneration, Jinan University, Guangzhou, P.R. China; Department of Ophthalmology, and State Key Laboratory of Cognitive and Brain Sciences, The University of Hong Kong, Hong Kong, P.R. China
- Huanxing Su** Department of Anatomy, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, China
- Zhida Su** Institute of Neuroscience and Key Laboratory of Molecular Neurobiology of Ministry of Education, Neuroscience Research Center of Changzheng Hospital, Second Military Medical University, Shanghai, China
- Chen Tian** National Laboratory for Physical Sciences at the Microscale, University of Science and Technology of China, China
- Veronica J. Tom** Department of Neurobiology and Anatomy and Drexel Spinal Cord Research Center, Drexel University College of Medicine, Philadelphia, PA, USA
- Chandler Walker** Spinal Cord and Brain Injury Research Group, Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Neurological Surgery and Goodman and Campbell Brain and Spine, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, USA
- Kevin K.W. Wang** Center for Neuroproteomics & Biomarkers Research, Department of Psychiatry, University of Florida, Gainesville, FL, USA; Department of Neuroscience, University of Florida, Gainesville, FL, USA; Taipei Medical University, Taipei, Taiwan, China
- Xiaofei Wang** Spinal Cord and Brain Injury Research Group, Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Neurological Surgery and Goodman and Campbell Brain and Spine, Indiana University School of Medicine, Indianapolis, IN, USA
- Wutian Wu** Department of Anatomy, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China; State Key Laboratory of Quality Research in Chinese Medicine, University of Macau, Macao, China; Institute of Chinese Medical Sciences, University of Macau, Macao SAR, China; Institute of CNS Regeneration, Jinan University and The University of Hong Kong, Guangzhou, China

- Xiao-Ming Xu** Spinal Cord and Brain Injury Research Group, Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Neurological Surgery and Goodman and Campbell Brain and Spine, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, USA
- Yumin Yang** Jiangsu Key Laboratory, Nantong University, Nantong, Jiangsu, P.R. China
- Wu Yin** National Laboratory for Physical Sciences at the Microscale, University of Science and Technology of China, China
- Wise Young** Department of Cell Biology & Neuroscience, W.M. Keck Center for Collaborative Neuroscience, Piscataway, NJ, USA
- Juliet C. Yuan** Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA
- Qiuju Yuan** Department of Anatomy, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China
- Guixin Zhang** Shriners Hospitals Pediatric Research Center, Temple University School of Medicine, Philadelphia, PA, USA
- Zhiqun Zhang** Center for Neuroproteomics & Biomarkers Research, Department of Psychiatry, University of Florida, Gainesville, FL, USA
- Binhai Zheng** Department of Neurosciences, University of California San Diego, La Jolla, California, USA
- Lihua Zhou** Department of Anatomy, Zhong Shan School of Medicine, Sun Yat-Sen University, Guangzhou, China
- Ruilin Zhu** Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA; Department of Ophthalmology, Peking University First Hospital, Beijing, China
- Su-qi Zou** National Laboratory for Physical Sciences at the Microscale, University of Science and Technology of China, China
- Yimin Zou** Neurobiology Section, Biological Sciences Division, University of California, San Diego, CA, USA

Contents

List of Contributors

ix

I

INTRODUCTION

1. Advances and Challenges for Neural Regeneration Research

XIAOFEI WANG, KWOK-FAI SO, XIAO-MING XU

- | | |
|---|----|
| 1. Nervous System, Nerve Injury, and Neural Regeneration | 3 |
| 2. Technological Advances in Neural Regeneration Research | 3 |
| 3. PNS Regeneration | 5 |
| 4. CNS Regeneration | 6 |
| 5. Challenges and Opportunities | 9 |
| Acknowledgments | 10 |
| References | 10 |

II

NEURAL REGENERATION IN LOWER VERTEBRATES

2. Functional Regeneration and Remyelination in the Zebrafish Optic Nerve

SU-QI ZOU, WU YIN, YU-BIN HUANG, CHEN TIAN, SHU-CHAO GE, BING HU

- | | |
|--|----|
| 1. Introduction to Zebrafish Optic Nerve Injury (ONI) as a Model for Studying Regeneration and Remyelination | 21 |
| 2. Time Course of Optic Nerve Regeneration in Adult Zebrafish | 21 |
| 3. Intrinsic and Extrinsic Mechanisms of Axon Regeneration | 24 |
| 4. Genetic Manipulation Tools are Very Useful for Studying Regeneration in Zebrafish | 27 |
| 5. In vivo Imaging of Nerve Regeneration in Zebrafish Larvae | 28 |
| 6. Imaging Remyelination in Zebrafish | 30 |
| 7. Behavior Tests Indexed the Visual Functional Recovery after Optic Nerve Injury | 32 |
| 8. Future Directions | 33 |
| 9. Conclusions | 33 |
| Acknowledgments | 33 |
| References | 34 |

3. Central Nerve Regeneration in Reptiles

JENNIFER RODGER, SARAH A. DUNLOP

- | | |
|--|----|
| 1. Introduction | 43 |
| 2. Timing of Regeneration—General Compared to Fish and Frogs, Including Geckos, etc. | 43 |

- | | |
|---|----|
| 3. Retinal Ganglion Cell Survival | 45 |
| 4. Glia: Friend or Foe? | 46 |
| 5. Growth Promotion: Neurotrophins, Extracellular Matrix, Gefitin, Polysialic Acid–Neural Cell Adhesion Molecule, Comparison with Development | 47 |
| 6. Topography and Refinement: NMDA/AMPA/GABA and Synaptic Proteins | 49 |
| 7. Conclusion: Relevance to Mammals | 50 |
| 8. Conclusions | 51 |
| Acknowledgments | 51 |
| References | 51 |

4. Axon Regeneration in the Lamprey Spinal Cord

MICHAEL I. SHIFMAN, MICHAEL E. SELZER

- | | |
|--|----|
| 1. The Need for Lower Vertebrate Models of Axon Regeneration in the Central Nervous System | 57 |
| 2. General Biology of the Lamprey | 58 |
| 3. The Central Nervous System of the Sea Lamprey | 58 |
| 4. Anatomical and Functional Evidence for Axon Regeneration in the Lamprey Spinal Cord | 60 |
| 5. Is Axon Regeneration a Recapitulation of Axon Development? | 62 |
| 6. Neuron-Intrinsic Determinants of Axon Regeneration | 63 |
| 7. Conclusions | 65 |
| References | 66 |

III

NEURAL REGENERATION IN THE PERIPHERAL NERVOUS SYSTEM

5. Tissue Engineering in Peripheral Nerve Regeneration

XIAOSONG GU, FEI DING, YUMIN YANG, JIE LIU

- | | |
|--------------------------|----|
| 1. Introduction | 73 |
| 2. Nerve Scaffolds | 73 |
| 3. Support Cells | 79 |
| 4. Growth Factors | 82 |
| 5. Clinical Applications | 86 |
| 6. Concluding Remarks | 86 |
| References | 87 |

6. Brachial Plexus Avulsion: A Model for Axonal Regeneration Study

HUANXING SU, QIUJU YUAN, LIHUA ZHOU, WUTIAN WU

- | | |
|--|-----|
| 1. Anatomy of Human and Rodent Brachial Plexus | 101 |
| 2. Brachial Plexus Avulsion | 101 |

3. Potential Strategies for the Treatment of Brachial Plexus Avulsion References	103 111	3. Technical Criteria for Selecting a CNS Axon Regeneration Drug Candidate 4. Drugs Targeting Myelin Molecules 5. Drug Candidates Targeting NgR1 6. Drugs Targeting NgR1 Signaling 7. Conclusion References	172 173 174 176 177 177
7. Conditions Affecting Accuracy of Peripheral Nerve Reinnervation and Functional Recovery TOBY A. FERGUSON, GEORGE M. SMITH		11. Astrogliosis and Axonal Regeneration KARTAVYA SHARMA, GUIXIN ZHANG, SHUXIN LI	
1. The Clinical Problem 2. Processes for Axonal Regeneration 3. Failure of Peripheral Nerve Regeneration 4. Improving Axon Targeting after Injury 5. Conclusions References	117 117 120 123 125 125	1. Astrogliosis after CNS Injury 2. Permissive and Nonpermissive Properties of Glial Scar 3. Molecular Mechanisms for CSPG Inhibition on Axonal Growth 4. Scar Tissue as a Target for Neuronal Repair and Regeneration 5. Conclusions and Prospects Acknowledgments References	181 184 186 189 191 192 192
8. Gonadal Steroids in Regeneration and Repair of Neuromuscular Systems EILEEN M. FOECKING, KEITH N. FARGO, TODD J. BROWN, DALE R. SENGELAUB, KATHRYN J. JONES		12. The Intrinsic Determinants of Axon Regeneration in the Central Nervous System KIN-SANG CHO, CHENYING GUO, JUSTIN CHEW, JULIET C. YUAN, RUILIN ZHU, ZHIGANG HE, DONG FENG CHEN	
1. Introduction 2. Gonadal Steroid Overview 3. Motoneuron Survival 4. Androgens and Axonal Regeneration 5. Androgens and Dendritic Morphology 6. Androgens and Peripheral Maintenance 7. Conclusion References	129 129 131 133 136 140 145 145	1. Introduction 2. Developmental Loss of Axon Regenerative Capacity 3. Role of cAMP in Neurite Growth and Regeneration 4. Mammalian Target of Rapamycin as a Central Player in Promoting Central Nervous System Axon Regeneration 5. KLFs and Their Role in Neuron Development and Axon Regeneration 6. Conclusion References	197 197 198 201 202 205 206
IV			
NEURAL REGENERATION IN THE CNS			
9. Myelin-Associated Inhibitors in Axonal Growth after Central Nervous System Injury CÉDRIC C. GEOFFROY, BINHAI ZHENG		13. Optic Nerve Regeneration in Lower Vertebrates and Mammals: Bridging the Gap YOSHIKI KORIYAMA, LARRY I. BENOWITZ	
1. Introduction 2. Brief History of Myelin Inhibition Research 3. Multiple Myelin-Associated Inhibitors 4. Multiple Receptors for Myelin-Associated Inhibitors 5. Other Inhibitory Molecules 6. Myelin-Associated Inhibitors and Axon Growth after Central Nervous System Injury in vivo 7. Concluding Remarks Acknowledgments References	153 153 154 156 158 160 165 165 165	1. Introduction 2. Cell Viability 3. Glial-Derived Inhibitors of Axon Growth 4. Control of the Regenerative State by Cell-Intrinsic and Cell-Extrinsic Factors 5. Intraocular Inflammation and Oncomodulin 6. Cell Signaling Pathways for Axon Regeneration of Retinal Ganglion Cells 7. Axon Guidance 8. Restoration of Central Visual Circuits and Partial Recovery of Visual Responses in Mammals 9. Future Prospects References	209 209 211 212 216 217 218 219 220 220
10. The Nogo Receptor Pathway in Central Nervous System Axon Regeneration and Therapeutic Opportunities DANIEL H.S. LEE			
1. Introduction 2. The Nogo and Nogo Receptor Pathway of CNS Axon Regeneration	171 172		

14. Self-Assembling Peptides Mediate Neural Regeneration

JIASONG GUO, KWOK-FAI SO, WUTIAN WU

1. Tissue Engineering is Essential for Neural Regeneration after Tissue Loss 229
2. SAP is a Kind of Novel Nanomaterial for Tissue Engineering 231
3. SAP Facilitates Neural Regeneration 232
- References 235

15. Wnt Signaling in Spinal Cord Injury

YIMIN ZOU

1. Introduction 237
2. Wnt Signaling in Axon Guidance 237
3. Wnt Signaling in Axon Responses to Spinal Cord Injury 241
- Acknowledgments 243
- References 243

16. Inflammation and Secondary Damage after Spinal Cord Injury

SAMUEL DAVID, ANTJE KRONER

1. Introduction 245
2. Early Injury Responses and Factors that Trigger Inflammation 246
3. Cellular Response to Spinal Cord Injury 250
4. Identification of Novel Targets that Mediate Inflammation and Secondary Damage after SCI 251
5. Critical Points in the Inflammatory Pathway in SCI Amenable to Therapeutic Intervention 255
6. Concluding Remarks 256
- Acknowledgments 256
- References 257

17. Neuroprotection of Retinal Ganglion Cells in Glaucoma by Blocking LINGO-1 Function or Using a Nogo-66 Receptor Antagonist

QING-LING FU, KWOK-FAI SO

1. Glaucoma 263
2. The Expression of Nogo, NgR, and LINGO-1 264
3. Neuroprotection of LINGO-1 Antagonists on RGCs in Glaucoma and the Possible Mechanism 265
4. Neuroprotection of NgR1 Antagonists on RGCs in Glaucoma 267
5. Summary 268
- References 268

18. Axonal Regeneration in the Sensory Dorsal Column Pathway

THEO HAGG

1. Historical Perspective 273
2. Conditioning Lesion 275

3. Sensory Axonal Regeneration 277
4. Technological Considerations 282
5. Future Directions 283
- Acknowledgments 283
- References 283

V

TRANSPLANTATION-MEDIATED NEURAL REGENERATION

19. Peripheral Nerve Graft-Mediated Axonal Regeneration

VERONICA J. TOM, JOHN D. HOULE

1. Introduction 291
2. Historical Perspective on PN Transplantation 291
3. Axonal Regeneration into a PNG 292
4. Grafting PNs to Promote Regeneration of Chronically Injured Axons 294
5. Effects of Exogenous Neurotrophins on Axon Regeneration beyond a PNG 295
- Acknowledgments 295
- References 296

20. Transplantation of Olfactory Ensheathing Cells for Neural Repair

ZHIDA SU, CHENG HE

1. Introduction 301
2. Contribution of OECs to Olfactory Axon Regeneration 301
3. Basic Biology of the Regeneration-Promoting Properties of OECs 302
4. OEC-Mediated Transplantation for Neural Repair in Animal Studies 306
5. OEC-Mediated Transplantation in Clinical Trials 311
6. Concluding Remarks 312
- References 312

21. Glial Precursor Cell Transplantation-Mediated Regeneration after Spinal Cord Injury Repair

QI LIN CAO

1. Therapeutic Potential of GPCs after SCI 321
2. Resources of GPCs for Potential Clinical Translation 325
3. The Challenges of Translating Stem Cell Therapies to the Clinic 328
4. Conclusions 330
- References 330

22. Schwann Cell-Mediated Axonal Regeneration in the Central Nervous System

LINGXIAO DENG, CHANDLER WALKER,
XIAO-MING XU

1. The Origin, Development, and Functions of Schwann Cells	337
2. The Application of SCs to Axonal Regeneration Following SCI	338
3. Potential Sources of SCs for Transplantation	338
4. The Survival and Migration of Grafted SCs	339
5. Reactions of Various Neuronal Tracts to Transplanted SCs	341
6. Combinatory Strategies to Conquer Limitations of Grafted SCs in Axon Regeneration	342
7. Clinical Application	344
8. Conclusion	345
Acknowledgments	345
References	346

23. Fetal Spinal Cord Transplantation after Spinal Cord Injury: Around and Back Again

LYN B. JAKEMAN, PAUL J. REIER

1. Introduction and History	351
2. Alternative Cell Sources for Spinal Tissue Repair	357
3. Revisiting FSC and Neural Progenitor Transplantation to Establish Functional Relays	360
4. Summary	361
References	361

3. Quality in Studies and Clinical Trials	374
4. Clinical Trials	375
5. Comparative Effectiveness Research (CER)	377
6. Summary and Conclusion	378
References	378

25. Spinal Cord Regeneration

WISE YOUNG

1. Introduction	383
2. Axon Growth Inhibitor Theory	383
3. Glial Scar Theory	384
4. Growth Limitation Theory	385
5. Regenerative Therapies	385
6. Cell Transplants	386
7. Combination Therapies	387
8. Recovery Mechanisms	387
9. Rehabilitation	388
References	389

26. Biomarkers for CNS Injury and Regeneration

KEVIN K.W. WANG, ZHIQUN ZHANG, AHMED MOGHIEB

1. Introduction	401
2. Acute Phase CNS Injury Protein Biomarkers	402
3. Need for Biochemical Markers of Subacute and Chronic CNS Injury	403
4. Subacute, Chronic CNS Injury Biomarkers	404
5. Post-TBI Neurodegeneration Markers	404
6. Neuroinflammatory Markers	405
7. Neuroregeneration Markers	405
8. Systems Biology-Assisted Biomarker Integration	405
References	406

VI

CLINICAL AND TRANSLATIONAL RESEARCH ON NEURAL REGENERATION

24. Spinal Cord Injury: Exercise and Clinical Trials

SARAH ALISON DUNLOP, MARY PAULINE GALEA

1. Spinal Cord Injury	369
2. Research Effort into Spinal Cord Injury and Exercise	370

27. High-Content Screening Applied to Nervous System Injury: Advantages, Challenges, and Proof of Principle

VANCE P. LEMMON, JOHN L. BIXBY

1. Introduction	411
2. High Content Analysis of Neuronal Functions	411
Acknowledgments	418
References	418

Index	421
--------------	------------

S E C T I O N I

INTRODUCTION

Advances and Challenges for Neural Regeneration Research

Xiaofei Wang^{1,2}, Kwok-Fai So^{4,5}, Xiao-Ming Xu^{1,2,3}

¹Spinal Cord and Brain Injury Research Group, Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA; ²Department of Neurological Surgery and Goodman and Campbell Brain and Spine, Indiana University School of Medicine, Indianapolis, IN, USA; ³Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, USA; ⁴GHM Institute of CNS Regeneration, Jinan University, Guangzhou, P.R. China; ⁵Department of Ophthalmology, and State Key Laboratory of Cognitive and Brain Sciences, The University of Hong Kong, Hong Kong, P.R. China

1. NERVOUS SYSTEM, NERVE INJURY, AND NEURAL REGENERATION

The nervous system is divided into two parts: the central nervous system (CNS), which consists of the brain and spinal cord, and the peripheral nervous system (PNS), which consists of cranial and spinal nerves along with their associated ganglia. The function of the CNS and PNS is to relay information to and from all parts of the body. This communication is made possible through an extensive network of neurons and supporting cells called glia, including astrocytes, oligodendrocytes, and microglia.

Nerve injury, whether traumatic or degenerative, disrupts the normal flow of information and can, depending on the location and mechanism of injury, lead to deleterious effects. Injury or sudden trauma, such as from automobile accidents, falls, sports-related activities, etc., can cause nerve fibers or axons to be partially or completely severed, crushed, compressed, or stretched. When an axon is damaged, the distal segment undergoes Wallerian degeneration, losing its myelin sheath [1]. The axotomized neurons either die by necrosis or apoptosis or undergo a chromatolytic reaction, which is an attempt to repair. Injury to the nervous system also triggers the responses of glial cells, including oligodendrocytes, astrocytes, and microglia in the CNS; Schwann cells (SCs) in the PNS; and blood-derived macrophages that participate in both CNS and PNS injury processes. The responses of these cells to injury include cell death,

proliferation, migration, and production of inflammatory mediators and growth factors, thus influencing processes of axonal degeneration and regeneration. Thus, nervous system injuries affect not only neurons and their processes but also glial cells.

Neural regeneration refers to the regrowth or repair of nervous tissues, cells, or cell products. Such mechanisms may include generation of new tissues, neurons, glia, axons, myelin, or synapses. Beyond the common knowledge of neurogenesis, a wider concept of neural regeneration may comprise endogenous neuroprotection leading to neuroplasticity and neurorestoration. Neural regeneration can also be promoted by implantation of viable tissues or cells. Neural regeneration differs between the PNS and the CNS owing to different neuronal and glia responses to injury as well as the different environments that the regenerative axons and cells encounter.

2. TECHNOLOGICAL ADVANCES IN NEURAL REGENERATION RESEARCH

2.1 Models

Preclinical animal models are critical for understanding regenerative neurobiology and for testing treatment strategies prior to implementation in clinical practice. For regeneration research, *in vitro*, *ex vivo*, or *in vivo* models, described below, have been used extensively and complementarily.

2.1.1 *In vitro* Model

The flexibility and ease of control offered by the *in vitro* model make it a useful tool for the study of neural regeneration. Glass micropipettes can be used to sever processes from cultured neurons or tissue explants to study axonal and dendritic regrowth *in vitro* [2–4]. Although this method can cut many axon segments simultaneously, it cannot be used to isolate axon and dendritic segments. Fine knife cutting is another localized physical injury, which can precisely cut neurites [5,6]; this method, however, damages the coated substrate and sets up an artificial sulcus, which may prevent the truncated neurite from regrowing. Microdissection of a neurite with a laser beam offers more precise control [7,8] that provides a unique platform for regeneration research [9]. A nanocutting device with a cutting edge of less than 20 nm radius of curvature was developed that enables high-precision microdissection and subcellular isolation of neuronal structures [10]. With these devices, not only can a single-axon transection model be established, but also regeneration-related functional components of neurons, such as segments of axons, dendrites, dendritic spines, and nodes of Ranvier, can be isolated in culture.

2.1.2 *Ex vivo* Model

An *ex vivo* model is ethically advantageous, requires no postsurgical animal care, enables more reproducibility between lesions, and provides a tightly controlled artificial environment for regeneration studies. Published *ex vivo* spinal cord models include the culture of several hundred micrometers-thick transverse slices maintained for up to three weeks [11], unfixed longitudinal cryostat sections of spinal cord maintained for one week [12], and a novel *ex vivo* model that enables the culture of intact postnatal spinal cord segments for up to five days and the assessment of peripheral nerve grafting repair [13].

2.1.3 *In vivo* Model

Although invertebrates and lower vertebrates, such as *Caenorhabditis elegans* [14–16], lamprey [17–19], zebrafish [20–23], and lizard [24,25], have long been applied for neural regeneration research, the rat sciatic nerve, brain, and spinal cord injury models have been the most commonly used for studies of neural regeneration. Rodent models, such as rats and mice, are economical compared to large-animal models and primates, simple to handle and care for, very resistant to surgical infections, and can be investigated in large groups. Rodent models can be used for electrophysiology, functional recovery, muscle and nerve morphology, and other assessments of nerve regeneration [26,27]. The major value of the mouse model is the ability to answer mechanistic neural

regeneration questions [28,29]. The rabbit, dog, and cat are large-animal species more frequently used for peripheral and central nervous system injury research. Large mammals such as sheep [30,31], pigs [32,33], and monkeys [34–37] have increasingly been employed to study neural regeneration. These large species are limited by extremely high costs related to animal care, the narrow range of assessments available, and the complexity of training for functional testing. Transgenic animals, particularly mice, that express fluorescent proteins in specific neuronal subsets provide potentially powerful tools for the study of neural regeneration. One strategy involves expressing fluorescent proteins under the control of neuron-type-specific promoters [38]. Another approach involves the use of bacterial artificial chromosome (BAC) mice [39,40]. Genetic labels can provide specificity in axonal labeling that is hypothetically independent of tracer transport [41]. Moreover, BAC mice bearing green fluorescent protein-tagged polyribosomes (BAC-TRAP mice) provide an exceptional opportunity to identify potential regeneration-associated transcriptional events in a cell-type-specific manner [40].

A book entitled *Animal Models of Acute Neurological Injuries* [42] has provided a wide array of animal models currently used for assessing acute neurological injuries, providing valuable resource for neural regeneration research.

2.2 Labeling and Imaging Technology

How to exquisitely label nerve fibers within the nerve system and their connections to their target continues to be an important concern for neural regeneration research. Transgenic animals that express fluorescent proteins in specific neuronal subsets provide potentially useful tools for the regeneration study of these neurons [38].

Axonal tract tracing technologies are also powerful tools for identifying axonal connections. With appropriate injury models and tracing techniques, the status of axons—sparing, die-back, sprouting, regeneration, or synaptogenesis—can be readily identified [43]. Based on axonal transport, a long series of tracers has been developed as anterograde tracing or retrograde tracing according to the preferential direction of their transport in the axon.

Viruses have been developed for tract-tracing studies. Compared to conventional tracers, viruses have the ability to traverse multisynaptic pathways and replicate to amplify signals at each step in the process [44]. Depending on the species and strain of the virus, viruses can travel preferentially in the anterograde or the retrograde direction or both [45,46]. For example, Wang et al. found that a recombinant adenovirus carrying a green fluorescent protein reporter gene (Adv-GFP) can preferentially, intensely, and bidirectionally label the rat rubrospinal

tract [46]. More recently, genetic modifications have allowed for many improvements. These include reduced pathogenicity, control of synaptic spread, addition of marker genes, pseudotyping for infection of selected cells, and addition of ancillary genetic elements for combining circuit tracing with manipulation of activity or functional assays.

Imaging plays an essential role in the diagnosis, treatment, and rehabilitation of nerve injury patients. Traditionally, imaging modalities have consisted of plain radiography, computed tomography, and magnetic resonance imaging (MRI). Despite their critical importance, these modalities offer comparatively less information regarding the microstructural changes after injury or regeneration. This has led to the development of novel imaging techniques that are principally focused on the microstructural and/or biochemical function of the nerve. These novel techniques include diffusion tensor imaging [47,48], MR spectroscopy [49,50], positron emission tomography [51,52], single-photon emission computed tomography [53,54], two-photon imaging [55,56], and functional MRI [57,58]. These techniques are currently in various development stages, including some whose applications are primarily limited to laboratory investigation, whereas others are being actively utilized in clinical practice. In 2011, a longitudinal coherent anti-Stokes Raman scattering imaging technique was reported to clearly monitor demyelination and remyelination of axons in live rats after spinal cord injury (SCI) [59]. A year later, a tetrahydrofuran-based clearing procedure that renders fixed and unsectioned adult CNS tissue transparent and fully penetrable for optical three-dimensional imaging was reported [60]. This procedure can be readily used to study neural regeneration.

2.3 Nanotechnology

The rapid expansion of nanotechnology during the past decade has led to new perspectives and advances in the neural regeneration field. As nanotechnology is defined by the size of a material or manipulation on the molecular level, it involves a broad range of nanoscaled materials used in various fields of regenerative medicine, including diagnosis, drug and gene delivery, tissue engineering (TE), and cell therapy. For example, to allow cells to be detected *in vivo*, superparamagnetic iron oxide nanoparticles have been successfully used to label transplanted cells for *in vivo* noninvasive MRI monitoring [61]. The basic strategy of TE is the construction of a biocompatible scaffold that, in combination with living cells and/or bioactive molecules, replaces or repairs damaged cells or tissue [62]. The large surface of nanostructured materials, such as two-dimensional (2D) electrospun nanofibers [63], 3D electrospun nanofibers [64,65], and self-assembling nanofibers [66,67], enhances the

adsorption of adhesive proteins, such as fibronectin, which mediate cell-surface interactions through integrin cell-surface receptors [68]. For example, the self-assembling peptide RADA16-I supported the growth of PC12 cells and the formation of functional synapses of rat primary hippocampal neurons [69]. Modification of the RADA16 peptide by the immobilization of bone marrow homing protein motifs significantly enhanced the survival of mouse neural cells [70]. *In vivo*, RADA16-I repairs the disrupted optic tract [71], bridges the injured spinal cord of rats after transplantation [72], and helps to reconstruct lost tissue in the acutely injured brain [73]. Injured spinal tissue incubated with self-assembled monomethoxy poly(ethylene glycol)-poly(D,L-lactic acid) diblock copolymer micelles (60 nm diameter) showed rapid restoration of compound action potential and reduced calcium influx into axons for micelle concentrations much lower than the concentrations of polyethylene glycol, a known sealing agent for early-stage SCI. Intravenously injected micelles effectively recovered locomotor function and reduced the volume and inflammatory response of the lesion in injured rats [74]. Trends in TE include scaffold functionalization that is tailored to each specific application and cell response. Improving the cellular response and the loading and delivery of drugs or bioactive molecules as well as enhancing the scaffolds' bioactivity can lead to the optimization of nanofibrous materials for transplantation and clinical application.

3. PNS REGENERATION

The PNS comprises axons of motor neurons, which stem from the brain/spinal cord and convey information from the CNS to muscle cells, and sensory neurons, whose cell bodies reside in ganglia and transmit information to the CNS. After peripheral nerve injury, axons can readily regenerate. PNS regeneration is remarkably efficient in mammals and closely mimics neurodevelopment. When a peripheral axon is severed, the tip of the proximal segment develops a growth cone, which then samples its environment for growth signals emitted by its target cells and extends toward them. PNS axons can regrow several centimeters in this fashion [75].

Neuronal intrinsic pathways are critical for PNS regeneration. Dorsal root ganglia (DRG) neurons show a strong regenerative capability when their peripheral branches, but not their central ones, are damaged [76,77]. Interestingly, the limited regenerative capacity of the central branches can be enhanced when their peripheral axons are damaged prior to, at the time of, or following the injury of their central axon, a phenomenon defined as the conditioning effect [76–78]. The first molecule to be implicated in this phenomenon was cyclic adenosine monophosphate (cAMP) [79–81]. These studies strongly

suggest that PNS neurons have an intrinsic regenerative capacity, and the DRG model can be used to investigate the molecular and genetic mechanisms driving PNS axonal regeneration. Costigan et al. compared gene expression profiles of DRGs after axotomy of the sciatic nerve to naive conditions, identifying 240 genes involved in immunity, inflammation, and neurotransmission that were associated with DRG axonal regeneration [82]. In the past few years, a number of regeneration-associated genes, such as growth-associated protein-43 [83], small proline-repeat protein 1A [84], KLF4, p53, signal transducer and activator of transcription 3 (STAT3), NFAT, RAR β , c-Jun [85], activating transcription factor-3 [86], and Sox11, have been identified as critical factors associated with PNS axonal regeneration [87,88]. Furthermore, a number of neurotrophins, including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophin 3 and 4, have been shown to initiate and contribute to the prosurvival and progrowth response of axotomized PNS neurons [89,90]. Delivery of these neurotrophic factors alone or combined with other strategies [91–94] promotes PNS regeneration.

An important extrinsic player in PNS regeneration is a type of PNS-supporting cell named the Schwann cell. SCs execute the combined functions of astrocytes and oligodendrocytes, myelinating axons and encasing synapses in the PNS [95]. After injury, the SCs become activated, assume a more primitive phenotype, and stimulate axonal growth, with upregulation of growth-related genes, including those that encode intrinsic neurotrophic factors and key transcription factors [96,97]. Activated SCs produce collagen and laminin, creating a tunnel of extracellular matrix, and express cell adhesion molecules and receptors, including interleukin-1, N-cadherin, γ -integrins, and the neural cell adhesion molecule [98]. The resulting supportive environment yields SC proliferation, formation of bands of Büngner, and, finally, supporting axonal growth. This growth occurs at a rate of 1–4 mm per day, with progressive myelination of the fibers by the neighboring SCs. The final repaired nerve usually presents thinner myelin sheets with shorter nodal lengths, less functional than the original nerve [99]. Based on their potential benefits, SCs have been extensively applied in peripheral nerve regeneration research [100–102].

PNS axonal regeneration requires a complex interaction of a scaffold for axonal elongation, supportive cells such as the Schwann cells, growth factors, and extracellular matrix [97,103]. When end-to-end suture of the nerve is not possible, the interposition of a nerve conduit becomes necessary. Autologous nerve grafts are considered the gold standard for repairing peripheral nerve gaps [104]. Autologous grafts are often harvested from the sural, or sensory, nerves [105]; however, sometimes there are limitations such as tissue availability,

size incompatibilities, and deformities. Less frequently, allografts can be used, with the disadvantages of requiring immunosuppression and of producing worse outcomes than autologous nerve grafts [106]. More recently, TE has provided nerve conduits, which function as guides for axonal regrowth. Depending on the materials used for their construction, nerve conduits can be classified as natural, based on laminin, collagen, or even vessels and decellularized nerves [107], or as artificial, usually made of polymers [108]. Although artificial, non-biodegradable scaffolds help nerve growth and provide beneficial results, they may lead to chronic inflammation and tissue compression and, therefore, must be surgically removed once the neural connection has been concluded. To avoid the hurdles of a second surgery on the injury site, biodegradable scaffolds are preferred [109]. The major limitation for use of nerve conduits is the low rate of axonal growth, which may not yield meaningful repair within the available time. Studies have shown that the conduits are effective in promoting repair of peripheral nerve gaps measuring up to 3 cm [108], whereas nerve autografts are required for bridging nerve gaps of larger distances.

4. CNS REGENERATION

In contrast to the PNS, in which severed axons often will regenerate, injured CNS neurons exhibit a burst of stymied growth but ultimately fail, with their axons stalling out and forming distinctive large endings dubbed “retraction bulbs” that fail to transverse the injury site. Numerous comparative studies have indicated phylogenetic differences in the regeneration capacity of various species. Whereas axons in the CNS of warm-blooded vertebrates (mammals and birds) do not regenerate, those in many lower vertebrates such as newts [110] can regenerate after injury. Young mammals are also capable of substantial CNS neural regeneration [111]. These studies demonstrate that the lack of CNS regeneration in warm-blooded vertebrates may be the result of evolutionary changes, although it is still unclear whether these varied responses are caused by differences in the expression of genes that are conserved across these organisms or by the presence of proteins that are specific to warm-blooded vertebrates. In the field’s effort to define the failure of axonal regeneration after CNS injury in mammals, the neuron’s intrinsic growth state, the glial scar, myelin inhibitors, and invading cells from the periphery have all been investigated as likely suspects involved in inhibiting CNS regeneration. Accordingly, numerous experimental research efforts aiming at these theories have been conducted and some exciting and promising interventions have been summarized below.

4.1 Intrinsic Growth Capability of CNS Neurons

As mentioned above, cAMP has been identified as the first molecule to be implicated in the conditioning effect [77,81]. Manipulation of signaling pathways by elevating the level of cAMP can similarly change a neuron's propensity to regenerate [77]. CNS neural regeneration can be enhanced *in vivo* by delivering a cAMP analog or by administering rolipram, which inhibits an enzyme that blocks the breakdown of cAMP [112,113]. Studies have also indicated that conditional knockout of PTEN (phosphatase and tensin homolog) or tuberous sclerosis complex 1, both negative regulators of the mammalian target of rapamycin (mTOR) pathway in adult retinal ganglion cells, promotes robust axon regeneration after optic nerve injury [114] and adult corticospinal tract [29], demonstrating that modulating neuronal intrinsic PTEN/mTOR activity represents a potential therapeutic strategy for promoting axon regeneration and functional repair after adult spinal cord injury [115]. More recently, the suppressor of cytokine signaling 3, a negative regulator of the Janus kinase/STAT pathway, was identified as another independent pathway that can act synergistically with PTEN/mTOR to promote enhanced axon regeneration [28,116].

4.2 The Glial Scar

Glial reaction is a hallmark of CNS injury. After CNS injury, astrocytes hyperproliferate and become "reactive," releasing extracellular matrix molecules, such as laminin, heparan, and especially chondroitin sulfate proteoglycans (CSPGs), which are considered to be major candidates for mediating the inhibitory activity of the scar [117]. Consistent with this possibility, therapeutic dissolution of the CSPG-rich matrix with chondroitinase ABC, an enzyme that selectively degrades CSPGs, has proven to be beneficial to axonal regeneration and functional recovery after SCI in preclinical studies in rodents [117–121]. In recent years this line of research has been further advanced with promising results [122–125]. Although it is well characterized that astrocytes produce several different CSPG family members that are differentially expressed after SCI [126–128], the molecular mechanisms through which CSPGs activate growth cone collapse are not fully understood. A transmembrane tyrosine phosphatase receptor, PTP σ , has been identified as one specific and high-binding-affinity receptor for CSPGs [129]. Subsequently, another member of the PTPR subfamily, LAR, was shown to bind to CSPGs with high affinity. Intervention with a LAR-targeting peptide improved axonal regeneration and motor functional recovery after SCI in rodents [130]. In addition, provocative reports have demonstrated that stromal cells

derived from pericytes, which control the vasculature in the CNS, also constitute a substantial portion of the cells found at the glial scar. Genetically modified animals with severely reduced populations of pericytes failed to insulate spinal cord lesions with glial scar tissue [131].

4.3 Myelin-Associated Inhibitors

The clearance of myelin debris is extremely slow within the adult mammalian CNS. As these remnants stay for weeks and months after lesion, the possibility was raised that residual myelin may contain factors that can actively prevent injured neurons from regenerating. *In vitro*, cultured neurons are prevented from extending axons when plated on purified myelin extracts [132,133]. *In vivo*, animals that received irradiation to impair the formation of myelin-producing oligodendrocytes, or were immunized with myelin extracts, showed some regeneration [133]. Since 2000, three prominent myelin-associated inhibitors (MAIs) have been identified: Nogo-A [134–137], myelin-associated glycoprotein (MAG) [138,139], and oligodendrocyte myelin glycoprotein (OMgp) [140–142]. The inhibitory properties of Nogo, MAG, and OMgp have been tested *in vitro* and *in vivo* in different CNS injury models [138,141,143–146], indicating Nogo-A as the major actor in myelin-dependent CNS repair failure. An anti-Nogo-A antibody has advanced to clinical trials for SCI (<http://www.research-projects.uzh.ch/p9471.htm>). The potential synergistic inhibitory effect of these three proteins on axonal regeneration in injured adult CNS has been tested. Triple-knockout (TKO) mice for Nogo, MAG, and OMgp were independently generated in two laboratories, and the axonal regenerative capacity of the corticospinal tract (CST) and 5-hydroxytryptamine (5-HT), as well as the motor functional recovery of the TKO mice, compared to wild-type and single-mutant mice, was evaluated after SCI. The Strittmatter lab found that loss of Nogo-A allows corticospinal and raphe-spinal axon growth above and below the injury, as well as greater behavioral recovery than in wild-type or heterozygous mutant mice. In contrast, deletion of MAG and OMgp stimulates neither axonal growth nor enhanced locomotion. The triple-mutant mice exhibit greater axonal growth and improved locomotion, consistent with a principal role for Nogo-A and synergistic actions for MAG and OMgp, presumably through shared receptors, which provide the optimal chance for overcoming myelin inhibition and improving neurological function [142]. The Zheng lab, however, found that, whereas deleting any one inhibitor in mice enhanced sprouting of corticospinal or raphe-spinal serotonergic axons, there was neither associated behavioral improvement nor a synergistic effect of deleting all three inhibitors. Furthermore, they found that triple-mutant mice failed to exhibit enhanced regeneration of either axonal tract after